Antiplatelet drug: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 40: Line 40:
== Is there a best third-generation antiplatelet drug?==
== Is there a best third-generation antiplatelet drug?==
The  ISAR-REACT 5 [[randomized controlled trial]] found benefit of [[prasugrel]] versus [[ticagrelor]] (primary outcome: 6.9% vs 9.3%; hazard ratio, 1.36; 95% confidence interval, 1.09 to 1.70; P = 0.006) among patients with "acute coronary syndromes and for whom invasive evaluation was planned"<ref name="pmid34708996">{{cite journal| author=Wang Y, Meng X, Wang A, Xie X, Pan Y, Johnston SC | display-authors=etal| title=Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA. | journal=N Engl J Med | year= 2021 | volume= 385 | issue= 27 | pages= 2520-2530 | pmid=34708996 | doi=10.1056/NEJMoa2111749 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=34708996  }}  [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=&cmd=prlinks&id=35226525 Review in: Ann Intern Med. 2022 Mar;175(3):JC30] </ref>.
The  ISAR-REACT 5 [[randomized controlled trial]] found benefit of [[prasugrel]] versus [[ticagrelor]] (primary outcome: 6.9% vs 9.3%; hazard ratio, 1.36; 95% confidence interval, 1.09 to 1.70; P = 0.006) among patients with "acute coronary syndromes and for whom invasive evaluation was planned"<ref name="pmid34708996">{{cite journal| author=Wang Y, Meng X, Wang A, Xie X, Pan Y, Johnston SC | display-authors=etal| title=Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA. | journal=N Engl J Med | year= 2021 | volume= 385 | issue= 27 | pages= 2520-2530 | pmid=34708996 | doi=10.1056/NEJMoa2111749 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=34708996  }}  [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=&cmd=prlinks&id=35226525 Review in: Ann Intern Med. 2022 Mar;175(3):JC30] </ref>.
The  POPular Genetics [[randomized controlled trial]] found faster onset of action but no benefit of [[cangrelor]] versus [[ticagrelor]] among patients with "ST-elevation myocardial infarction (STEMI) population treated with primary percutaneous coronary intervention (PPCI"<ref name="pmid31129911">{{cite journal| author=Ubaid S, Ford TJ, Berry C, Murray HM, Wrigley B, Khan N | display-authors=etal| title=Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial. | journal=Thromb Haemost | year= 2019 | volume= 119 | issue= 7 | pages= 1171-1181 | pmid=31129911 | doi=10.1055/s-0039-1688789 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31129911  }} </ref>.


==Should drug selection be driven by genetic testing and platelet function testing?==
==Should drug selection be driven by genetic testing and platelet function testing?==

Revision as of 17:32, 14 August 2022

WikiDoc Resources for Antiplatelet drug

Articles

Most recent articles on Antiplatelet drug

Most cited articles on Antiplatelet drug

Review articles on Antiplatelet drug

Articles on Antiplatelet drug in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Antiplatelet drug

Images of Antiplatelet drug

Photos of Antiplatelet drug

Podcasts & MP3s on Antiplatelet drug

Videos on Antiplatelet drug

Evidence Based Medicine

Cochrane Collaboration on Antiplatelet drug

Bandolier on Antiplatelet drug

TRIP on Antiplatelet drug

Clinical Trials

Ongoing Trials on Antiplatelet drug at Clinical Trials.gov

Trial results on Antiplatelet drug

Clinical Trials on Antiplatelet drug at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Antiplatelet drug

NICE Guidance on Antiplatelet drug

NHS PRODIGY Guidance

FDA on Antiplatelet drug

CDC on Antiplatelet drug

Books

Books on Antiplatelet drug

News

Antiplatelet drug in the news

Be alerted to news on Antiplatelet drug

News trends on Antiplatelet drug

Commentary

Blogs on Antiplatelet drug

Definitions

Definitions of Antiplatelet drug

Patient Resources / Community

Patient resources on Antiplatelet drug

Discussion groups on Antiplatelet drug

Patient Handouts on Antiplatelet drug

Directions to Hospitals Treating Antiplatelet drug

Risk calculators and risk factors for Antiplatelet drug

Healthcare Provider Resources

Symptoms of Antiplatelet drug

Causes & Risk Factors for Antiplatelet drug

Diagnostic studies for Antiplatelet drug

Treatment of Antiplatelet drug

Continuing Medical Education (CME)

CME Programs on Antiplatelet drug

International

Antiplatelet drug en Espanol

Antiplatelet drug en Francais

Business

Antiplatelet drug in the Marketplace

Patents on Antiplatelet drug

Experimental / Informatics

List of terms related to Antiplatelet drug

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

An antiplatelet drug is a member of a class of pharmaceuticals that decreases platelet aggregation and inhibits thrombus formation. They are effective in the arterial circulation, where anticoagulants have little effect.

They are widely used in primary and secondary prevention of thrombotic cerebrovascular or cardiovascular disease.

The Most Important Antiplatelet Drugs

Are third-generation agents better than second-generation agents?

Studies of all patients

The ALPHEUS randomized controlled trial found no benefit of ticagrelor versus clopidogrel among stable coronary patients undergoing high-risk elective PCI (primary outcome in 35% vs 36% of patients)[1].


The POPular AGE randomized controlled trial found no benefit of ticagrelor versus clopidogrel among patients aged 70 years or older with non-ST-elevation acute coronary syndrome (MACE in 11% vs 12% of patients)[2]


Studies of patients with CYP2C19 loss-of-function =

The CHANCE-2 randomized controlled trial found benefit of ticagrelor versus clopidogrel (primary outcome: 6% vs 7.6%; hazard ratio, 0.77; 95% confidence interval, 0.64 to 0.94; P = 0.008) among Chinese patients with minor ischemic stroke or transient ischemic attack (TIA) who carried CYP2C19 loss-of-function alleles[3].


Is there a best third-generation antiplatelet drug?

The ISAR-REACT 5 randomized controlled trial found benefit of prasugrel versus ticagrelor (primary outcome: 6.9% vs 9.3%; hazard ratio, 1.36; 95% confidence interval, 1.09 to 1.70; P = 0.006) among patients with "acute coronary syndromes and for whom invasive evaluation was planned"[3].


The POPular Genetics randomized controlled trial found faster onset of action but no benefit of cangrelor versus ticagrelor among patients with "ST-elevation myocardial infarction (STEMI) population treated with primary percutaneous coronary intervention (PPCI"[4].

Should drug selection be driven by genetic testing and platelet function testing?

Guided therapy (drug choice based on genetic testing and platelet function testing may improve outcomes according to a systematic reveiw[5].

However, the key POPular Genetics randomized controlled trial found no benefit from a CYP2C19 guided therapy (primary outcome: 5.1 vs 5.9%;P = 0.44) among patients undergoing primary PCI with stent implantation[6].

See also

External links

References

  1. Silvain J, Lattuca B, Beygui F, Rangé G, Motovska Z, Dillinger JG; et al. (2020). "Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial". Lancet. 396 (10264): 1737–1744. doi:10.1016/S0140-6736(20)32236-4. PMID 33202219 Check |pmid= value (help).
  2. Gimbel M, Qaderdan K, Willemsen L, Hermanides R, Bergmeijer T, de Vrey E; et al. (2020). "Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial". Lancet. 395 (10233): 1374–1381. doi:10.1016/S0140-6736(20)30325-1. PMID 32334703 Check |pmid= value (help). Review in: Ann Intern Med. 2020 Sep 15;173(6):JC28
  3. 3.0 3.1 Wang Y, Meng X, Wang A, Xie X, Pan Y, Johnston SC; et al. (2021). "Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA". N Engl J Med. 385 (27): 2520–2530. doi:10.1056/NEJMoa2111749. PMID 34708996 Check |pmid= value (help). Review in: Ann Intern Med. 2022 Mar;175(3):JC30
  4. Ubaid S, Ford TJ, Berry C, Murray HM, Wrigley B, Khan N; et al. (2019). "Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial". Thromb Haemost. 119 (7): 1171–1181. doi:10.1055/s-0039-1688789. PMID 31129911.
  5. Galli M, Benenati S, Capodanno D, Franchi F, Rollini F, D'Amario D; et al. (2021). "Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis". Lancet. 397 (10283): 1470–1483. doi:10.1016/S0140-6736(21)00533-X. PMID 33865495 Check |pmid= value (help).
  6. Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van 't Hof AWJ, van der Harst P; et al. (2019). "A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI". N Engl J Med. 381 (17): 1621–1631. doi:10.1056/NEJMoa1907096. PMID 31479209.

Template:Major Drug Groups

Template:WH Template:WS